Welcome to our dedicated page for Harvard Apparatus Regenerative Technology SEC filings (Ticker: HRGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harvard Apparatus Regenerative Technology, Inc. (HRGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Harvard Apparatus Regenerative Technology describes itself as a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs, and its filings offer detail on how it funds and governs these activities.
Through documents such as Forms 10-K and 10-Q, investors can review the company’s reported financial results, operating expenses related to research and development, sales and marketing, and general and administrative activities, as well as information on cash balances, financing arrangements and accumulated deficits. Current reports on Form 8-K, including filings describing Securities Purchase Agreements for private placements of common stock, outline material events such as unregistered sales of equity securities and other significant corporate developments.
For a company like HRGN, which reports multiple private placements and PIPE financings to support its clinical programs, these filings can help readers understand the terms of capital raises, risk factors and other disclosures referenced in its press releases. Over time, proxy statements and other governance-related filings can also provide information on board composition and corporate structure, while Form 4 and related insider transaction reports, when available, can show equity transactions by officers, directors or significant shareholders.
Stock Titan enhances access to these materials with AI-powered summaries that highlight key points from lengthy filings, helping readers interpret complex sections on financing terms, clinical-stage risks and other disclosures. Filings are updated in near real time from the SEC’s EDGAR system, allowing users to track new 8-Ks, 10-Qs, 10-Ks and other forms related to Harvard Apparatus Regenerative Technology as they are made public.
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors for a private placement of its common stock. The investors agreed to buy an aggregate of 411,765 shares of common stock at a purchase price of $1.70 per share, for an aggregate purchase price of approximately $0.7 million.
The shares were sold in a private transaction relying on exemptions from Securities Act registration, including Section 4(a)(2) for transactions not involving a public offering and Rule 506 for sales to an accredited investor, as well as similar state law exemptions. The Purchase Agreements contain customary representations, warranties, and covenants, and a form of the agreement is filed as an exhibit to the report.
Harvard Apparatus Regenerative Technology, Inc. reported an insider share purchase by its CEO. The company’s Chief Executive Officer and Director, based on this filing, bought 3,000 shares of common stock on 11/25/2025 in an open-market transaction coded “P” for a purchase. The weighted average purchase price reported was $1.70 per share, reflecting multiple trades between November 25 and November 26. Following this transaction, the reporting person beneficially owned 280,575 shares of Harvard Apparatus Regenerative Technology common stock held directly.
Harvard Apparatus Regenerative Technology (HRGN) filed its Q3 2025 10‑Q, reporting higher consumer health sales on a small base and continued operating losses, alongside a going concern warning. Q3 product revenue was $123,000 (vs. $59,000 a year ago), and the net loss was $1.7 million (vs. $1.9 million). For the first nine months, revenue reached $485,000 (vs. $172,000), while the net loss narrowed to $5.2 million (vs. $6.4 million), helped by lower selling, marketing, and G&A expenses.
Cash and equivalents were $1.3 million at September 30, 2025. Management states these funds are expected to support operations into the fourth quarter of 2025, raising substantial doubt about the company’s ability to continue as a going concern. The company completed a private placement on July 11, 2025, issuing 1,250,000 shares for gross proceeds of
Deferred revenue was $128,000, and warrants outstanding totaled 898,622 with a weighted‑average exercise price of
He Junli, who serves as Chief Executive Officer and a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), purchased 11,225 shares of HRGN common stock in transactions executed between September 2, 2025 and September 22, 2025 at a weighted average price of $1.85 per share. Following these purchases the reporting person beneficially owned 277,275 shares. The Form 4 was signed by a power of attorney on September 24, 2025. The filing discloses no derivative transactions and notes the weighted average price reflects multiple trades; the reporting person will supply transaction-level price details on request.